New antibody combo targets tough blood cancers
Disease control
Ongoing
This study tests a new drug called bexmarilimab, given with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The first part finds a safe dose, and the second part checks if the combination helps control the cancer. About 181 adults will take part.
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC